Terms: = Lung cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Treatment
68 results:
1. 25-hydroxycholesterol promotes proliferation and metastasis of lung adenocarcinoma cells by regulating ERβ/tnfrsf17 axis.
He M; Jiang W; Li X; Liu H; Ren H; Lin Y
BMC Cancer; 2024 Apr; 24(1):505. PubMed ID: 38649856
[TBL] [Abstract] [Full Text] [Related]
2. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
Meng M; Liu X; Liang X; Chen X; Li Y
Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
[TBL] [Abstract] [Full Text] [Related]
3. Albumin-to-D-dimer ratios: A novel prognostic factor for evaluating first-line chemotherapy efficacy in advanced lung adenocarcinoma patients.
Zhang L; Li X; Wang Z; Zhang Z; Zhang L; Liu Z; Zhang L; Wang S; Khorobrykh TV; He M; Xiao J
Neoplasma; 2024 Feb; 71(1):77-87. PubMed ID: 38506032
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of pretreatment albumin-bilirubin (ALBI) grade and platelet-albumin-bilirubin (PALBI) grade in patients with small cell lung cancer.
Kut E; Menekse S
Sci Rep; 2024 Jan; 14(1):1371. PubMed ID: 38228667
[TBL] [Abstract] [Full Text] [Related]
5. Swallowing disorders and mortality in adults with advanced cancer outside the head and neck and upper gastrointestinal tract: a systematic review.
Silva DNM; Vicente LCC; Glória VLP; de Lima Friche AA
BMC Palliat Care; 2023 Oct; 22(1):150. PubMed ID: 37798715
[TBL] [Abstract] [Full Text] [Related]
6. Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Han X; Wang M; Zheng Y; Wang N; Wu Y; Ding C; Jia X; Yang R; Geng M; Chen Z; Zhang S; Zhang K; Li Y; Liu J; Gu J; Liao Y; Fan J; Shi H
Eur Radiol; 2024 Apr; 34(4):2716-2726. PubMed ID: 37736804
[TBL] [Abstract] [Full Text] [Related]
7. Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
Kuan AS; Chiang CL; Wu HM; Yang HC; Chen CJ; Lin CJ; Guo WY; Pan DH; Chung WY; Lee CC
J Neurooncol; 2023 Sep; 164(3):729-739. PubMed ID: 37721662
[TBL] [Abstract] [Full Text] [Related]
8. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract] [Full Text] [Related]
9. Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non-small cell lung cancer patients.
Tan X; Wang S; Xia H; Chen H; Xu J; Meng D; Wang Z; Li Y; Yang L; Jin Y
Invest New Drugs; 2023 Jun; 41(3):463-472. PubMed ID: 37140694
[TBL] [Abstract] [Full Text] [Related]
10. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I
Lancet; 2023 May; 401(10390):1773-1785. PubMed ID: 37086745
[TBL] [Abstract] [Full Text] [Related]
11. Better survival and prognosis in SCLC survivors after combined second primary malignancies: A SEER database-based study.
Wang S; Hu S; Huang S; Su L; Guo Q; Wu B; Ye J; Zhang D; Zhang Y; Zhang W; Wei Y
Medicine (Baltimore); 2023 Feb; 102(6):e32772. PubMed ID: 36820587
[TBL] [Abstract] [Full Text] [Related]
12. Trends in Survival and Surgical Methods in Patients Surgically Treated for Metastatic Spinal Tumors: 25-Year Experience in a Single Institution.
Park SJ; Park JS; Lee CS; Kang BJ; Jung CW
Clin Orthop Surg; 2023 Feb; 15(1):109-117. PubMed ID: 36778984
[TBL] [Abstract] [Full Text] [Related]
13. Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study.
Turtle L; Thorpe M; Drake TM; Swets M; Palmieri C; Russell CD; Ho A; Aston S; Wootton DG; Richter A; de Silva TI; Hardwick HE; Leeming G; Law A; Openshaw PJM; Harrison EM; ; Baillie JK; Semple MG; Docherty AB
PLoS Med; 2023 Jan; 20(1):e1004086. PubMed ID: 36719907
[TBL] [Abstract] [Full Text] [Related]
14. A comprehensive bioinformatics analysis of FOXP3 in nonsmall cell lung cancer.
Zhu J; Li Z; Chen J; Li W; Wang H; Jiang T; Ma Y
Medicine (Baltimore); 2022 Dec; 101(50):e32102. PubMed ID: 36550816
[TBL] [Abstract] [Full Text] [Related]
15. Evaluate the Prognosis of
Cao J; J Gu J; Liang Y; Wang B
Technol Cancer Res Treat; 2022; 21():15330338221138213. PubMed ID: 36524293
[No Abstract] [Full Text] [Related]
16. Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor-node-metastasis stages in patients with non-small cell lung cancer.
Cheng H; Bhushan S; Li N; Xiao Z; Gao K
J Cancer Res Ther; 2022; 18(6):1666-1673. PubMed ID: 36412428
[TBL] [Abstract] [Full Text] [Related]
17. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive analysis of CXCR family members in lung adenocarcinoma with prognostic values.
Hu LT; Deng WJ; Chu ZS; Sun L; Zhang CB; Lu SZ; Weng JR; Ren QS; Dong XY; Li WD; Li XB; Du YT; Li Y; Wang WQ
BMC Pulm Med; 2022 Jun; 22(1):259. PubMed ID: 35768814
[TBL] [Abstract] [Full Text] [Related]
19. The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.
Gasperoni L; Cafaro A; Ferretti E; Di Iorio V; Nanni O; Masini C
Eur J Hosp Pharm; 2023 Mar; 30(2):96-100. PubMed ID: 35577545
[TBL] [Abstract] [Full Text] [Related]
20. The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors.
Schakenraad A; Hashemi S; Twisk J; Houda I; Ulas E; Daniels JMA; Veltman J; Bahce I
Lung Cancer; 2021 Dec; 162():36-41. PubMed ID: 34666276
[TBL] [Abstract] [Full Text] [Related]
[Next]
